TPI 287 in Patients With Recurrent Glioblastoma Multiforme

PHASE2TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

December 31, 2012

Conditions
Brain Cancer
Interventions
DRUG

TPI 287

Starting dose of 160 mg/m\^2 as a 60-minute (± 10 minutes) IV infusion once every 3 weeks, (i.e., 1 cycle = 21 days).

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cortice Biosciences, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT01113463 - TPI 287 in Patients With Recurrent Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter